Drug Design Novel Advances in the Omics Field and Applications

Right before the COVID-19 pandemic declared by the World Health Organization (WHO), life sciences have incited novel areas of studies that revolutionize the health sector. They are the studies of structural bioinformatics, pharmacogenomics, and metabolomics. The structural bioinformatics field is th...

Full description

Bibliographic Details
Main Author: Aditya Parikesit, Arli
Format: eBook
Language:English
Published: IntechOpen 2021
Subjects:
Online Access:
Collection: Directory of Open Access Books - Collection details see MPG.ReNa
LEADER 02028nma a2200313 u 4500
001 EB002205985
003 EBX01000000000000001343186
005 00000000000000.0
007 cr|||||||||||||||||||||
008 240502 ||| eng
020 |a 9781789852011 
020 |a intechopen.87640 
020 |a 9781789847529 
020 |a 9781789847536 
100 1 |a Aditya Parikesit, Arli 
245 0 0 |a Drug Design  |h Elektronische Ressource  |b Novel Advances in the Omics Field and Applications 
260 |b IntechOpen  |c 2021 
300 |a 1 electronic resource (158 p.) 
653 |a bioactive compounds, drug discovery, genomics, proteomics, density functional theory, metabolites 
653 |a Pharmacology / bicssc 
700 1 |a Aditya Parikesit, Arli 
041 0 7 |a eng  |2 ISO 639-2 
989 |b DOAB  |a Directory of Open Access Books 
500 |a Creative Commons (cc), https://creativecommons.org/licenses/by/3.0/ 
024 8 |a 10.5772/intechopen.87640 
856 4 2 |u https://directory.doabooks.org/handle/20.500.12854/130927  |z DOAB: description of the publication 
856 4 0 |u https://mts.intechopen.com/storage/books/9831/authors_book/authors_book.pdf  |7 0  |x Verlag  |3 Volltext 
082 0 |a 615 
520 |a Right before the COVID-19 pandemic declared by the World Health Organization (WHO), life sciences have incited novel areas of studies that revolutionize the health sector. They are the studies of structural bioinformatics, pharmacogenomics, and metabolomics. The structural bioinformatics field is the very foundation of drug design research, as it provides insight into the molecular simulations and interactions between the biomolecules and the drug candidates. Secondly, pharmacogenomics is the starting point of any efforts in developing personalized medicine. Lastly, metabolomics provides instrumentation to elicit biomarkers for various diseases and health conditions. These studies have enabled current accelerated effort in COVID-19 research, as well as other communicable and non-communicable diseases.